Assertio (ASRT) Small-Cap Growth Virtual Investor Conference summary

Financial performance and guidance

• Ended Q1 with $80.7 million in cash, up from $70 million at the start of the year, and net cash of $40 million after accounting for $40 million in debt maturing in 2027.

• Q1 net product sales reached $31.9 million, with operating cash flows of $7.5 million.

• 2024 guidance reaffirmed: product sales expected between $110 million–$125 million, adjusted EBITDA $20 million–$30 million, and year-end cash projected at $90 million–$100 million.

• Profitability and cash flow growth are driven by a lean omni-channel commercial strategy and prudent operational management.

• Indocin, now generic, is expected to contribute $18 million–$25 million in 2024.

Product portfolio and growth drivers

• Portfolio centers on five main products: Rolvedon, Sympazan, Otrexup, Sprix, and Indocin.

• Rolvedon, a PEG injection for oncology, is the primary growth driver, expected to generate $60 million in 2024 and potentially $100 million in coming years.

• Sympazan and Otrexup offer differentiated delivery systems and patent protection into the next decade.

• Sprix provides opioid-level pain relief without being an opioid, and Indocin is managed for long-term profitability post-exclusivity.

• Rolvedon and Sympazan are prioritized for investment due to growth potential and market differentiation.

Rolvedon market opportunity and strategy

• Rolvedon operates in a $1 billion+ PEG injection market, mainly targeting community oncology clinics.

• Demand for Rolvedon has shown strong sequential growth, with Q1 2024 being a standout quarter.

• Rolvedon benefits from unique patent protection through 2039 and a distinct reimbursement model, allowing pricing independence from biosimilars.

• A same-day dosing trial is underway, which could further expand market potential if successful.

• Channel inventory and incentive programs were optimized post-acquisition to align sales with true demand and protect long-term profitability.